Indian drug discovery and research company, NovaLead Pharma Private Limited, is set to trial its repurposed COVID-19 drug, which is code-named NLP21. The company claims the drug has shown better efficacy than all the other existing treatments currently being used in the treatment of COVID-19. The country's top drug regulator, Drug Controller General of India (DCGI), has recently granted approval to NovaLead "in principle" to undertake clinical trials for its repurposed drug.
(All Fields Required)
Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.
×Contact Us
For More Info!
